Reports of Biochemistry
and Molecular Biology
Tue, Dec 3, 2024
[Archive]
Volume 11, Issue 4 (Vol.11 No.4 Jan 2023)
rbmb.net 2023, 11(4): 694-701 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nurtleu M, Adish Z, Mukanov K, Tursunov K, Ramankulov Y, Mukantayev K. Analysis of Antibody Induction by Macrophages Treated Ex Vivo with Human Proteins in Mice. rbmb.net 2023; 11 (4) :694-701
URL: http://rbmb.net/article-1-986-en.html
URL: http://rbmb.net/article-1-986-en.html
Malika Nurtleu 
, Zhansaya Adish , Kasym Mukanov , Kanat Tursunov * , Yerlan Ramankulov , Kanatbek Mukantayev
, Zhansaya Adish , Kasym Mukanov , Kanat Tursunov * , Yerlan Ramankulov , Kanatbek Mukantayev
1: Republican State Enterprise National Center for Biotechnology, Ministry of Healthcare of the Republic of Kazakhstan, Nur-Sultan, 010000, Kazakhstan.
Abstract: (1691 Views)
Background: Macrophages are essential cellular components in various body tissues and tumor microenvironments. The high infiltration of macrophages into the tumor microenvironment determines the importance of ex vivo treatment of personalized macrophages with recombinant cytotoxic T-lymphocyte-associated protein 4 (rCTLA-4), programmed death-ligand 1 (rPD-L1), and programmed cell death protein 1 (rPD-1) proteins to block immune checkpoints.
Methods: We investigated the development of humoral immunity against CTLA-4, PD-L1, and PD-1 receptors by introducing macrophages treated ex vivo with the corresponding proteins into mice. Peritoneal macrophages from BALB/c mice were cultured in medium containing recombinant human CTLA-4, PD-L1, and PD-1 proteins. Macrophages processing recombinant proteins were analyzed via immunofluorescence staining using antibodies against CTLA-4, PD-L1, and PD-1. The treated macrophages were administered intraperitoneally to mice to induce anti-CTLA-4, anti-PD-L1, and anti-PD-1 antibodies. The antibody titer in vaccinated mice was determined via enzyme-linked immunosorbent assays, followed by statistical analysis of the results.
The specificity of the antibodies was determined via immunofluorescence staining in MCF7 cells.
Results: The ex vivo treatment of macrophages with rCTLA-4, rPD-L1, and rPD-1 induced the formation of specific antibodies in vaccinated mice. The various rPD-L1 and rPD-1 concentrations used to treat macrophages had no significant effect on the specific antibody titers, while the anti-rCTLA-4 titer was dependent on the protein concentration in the culture medium. Immunofluorescence analysis revealed that anti-CTLA-4 and PD-L1 antibodies reacted with MCF7 cells.
Conclusions: The ex vivo treatment of macrophages with rCTLA-4, rPD-L1, and rPD-1 can help induce humoral immunity and develop new approaches for cancer immunotherapy.
Methods: We investigated the development of humoral immunity against CTLA-4, PD-L1, and PD-1 receptors by introducing macrophages treated ex vivo with the corresponding proteins into mice. Peritoneal macrophages from BALB/c mice were cultured in medium containing recombinant human CTLA-4, PD-L1, and PD-1 proteins. Macrophages processing recombinant proteins were analyzed via immunofluorescence staining using antibodies against CTLA-4, PD-L1, and PD-1. The treated macrophages were administered intraperitoneally to mice to induce anti-CTLA-4, anti-PD-L1, and anti-PD-1 antibodies. The antibody titer in vaccinated mice was determined via enzyme-linked immunosorbent assays, followed by statistical analysis of the results.
The specificity of the antibodies was determined via immunofluorescence staining in MCF7 cells.
Results: The ex vivo treatment of macrophages with rCTLA-4, rPD-L1, and rPD-1 induced the formation of specific antibodies in vaccinated mice. The various rPD-L1 and rPD-1 concentrations used to treat macrophages had no significant effect on the specific antibody titers, while the anti-rCTLA-4 titer was dependent on the protein concentration in the culture medium. Immunofluorescence analysis revealed that anti-CTLA-4 and PD-L1 antibodies reacted with MCF7 cells.
Conclusions: The ex vivo treatment of macrophages with rCTLA-4, rPD-L1, and rPD-1 can help induce humoral immunity and develop new approaches for cancer immunotherapy.
Keywords: Cytotoxic T Lymphocyte-Associated Protein 4, Immunotherapy, Macrophages, Programmed Death-Ligand 1, Programmed Cell Death Protein 1.
Type of Article: Original Article |
Subject:
Immunology
Received: 2022/07/1 | Accepted: 2022/07/20 | Published: 2023/04/3
Received: 2022/07/1 | Accepted: 2022/07/20 | Published: 2023/04/3
References
1. Ralph M, Steinman MD. Dendritic cells and vaccines. Baylor University Medical Center Proceedings. 2008;21(1):3-8. [DOI:10.1080/08998280.2008.11928346] [PMID] [PMCID]
2. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245-252. [DOI:10.1038/32588] [PMID]
3. Perica K, De León Medero A, Durai M, Chiu YL, Bieler JG, Sibener L, et al. Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine. 2014;10(1):119-129. [DOI:10.1016/j.nano.2013.06.015] [PMID] [PMCID]
4. Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, et al. Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clin Cancer Research. 2020;26(13):3384-3396. [DOI:10.1158/1078-0432.CCR-19-3487] [PMID] [PMCID]
5. Cendrowicz E, Zuzanna S, Bremer E, Rygiel TP. The Role of Macrophages in Cancer Development and Therapy. Cancers (Basel). 2021;13(8):1946. [DOI:10.3390/cancers13081946] [PMID] [PMCID]
6. Sharma N, Agrewala JN. Potent Role of Vaccines Prepared from Macrophages Infected with Live Bacteria in Protection against Mycobacterium tuberculosis and Salmonella typhimurium Infections. The Journal of Infectious Diseases. 2004;190:107-14. [DOI:10.1086/421116] [PMID]
7. Chavez M, Silvestrini MT, Ingham ES, Fite BZ, Mahakian LM, Tam SM, et al. Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation. Theranostics. 2018;8(13):3611-2368. [DOI:10.7150/thno.25613] [PMID] [PMCID]
8. Harari A, Graciotti M, Bassani-Sternberg M. Antitumour dendritic cell vaccination in a priming and boosting approach. Nature Reviews Drug Discovery. 2020;19:635-652. [DOI:10.1038/s41573-020-0074-8] [PMID]
9. Eiz-Vesper B, Schmetzer HM. Antigen-Presenting Cells: Potential of Proven und New Players in Immune Therapies. Transfus Med Hemother. 2020;47(6):429-431. [DOI:10.1159/000512729] [PMID] [PMCID]
10. Kelly PN. More DC subtypes revealed. Science. 2019;366(6470):1210. [DOI:10.1126/science.366.6470.1210-b]
11. Patente TA, Pinho MP, Oliveira AA, Evangelista GC, Bergami-Santos PC, Barbuto JA. Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. Frontiers in Immunology. 2019;9:3176. [DOI:10.3389/fimmu.2018.03176] [PMID] [PMCID]
12. Garofano F, Gonzalez-Carmona MA, Skowasch D, Schmidt-Wolf R, Abramian A, Hauser S, et al. Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. Int J Mol Sci. 2019;20(17):4307. [DOI:10.3390/ijms20174307] [PMID] [PMCID]
13. Bialek-Waldmann JK, Heuser M, Ganser A, Stripecke R. Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. Cancer Immunology, Immunotherapy. 2019; 68(11):1891-1899. [DOI:10.1007/s00262-019-02406-9] [PMID] [PMCID]
14. Muntjewerff EM, Meesters LD, Van den Bogaart G. Antigen Cross-Presentation by Macrophages. Front Immunol. 2020;11:1276. [DOI:10.3389/fimmu.2020.01276] [PMID] [PMCID]
15. Chu KL, Batista NV, Girard M. Monocyte-derived cells in tissue-resident memory T cell formation. Journal Immunol. 2020;204:477-85. [DOI:10.4049/jimmunol.1901046] [PMID]
16. Kim CG, Sang YB, Lee JH, Chon HJ. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. International Journal of Molecular Science. 2021;22(15):8035. [DOI:10.3390/ijms22158035] [PMID] [PMCID]
17. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265-77. [DOI:10.1038/nrc3258] [PMID] [PMCID]
18. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197-218. [DOI:10.1038/s41573-018-0007-y] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
